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The hemodynamic and hormonal responses to nitrogly-
cerin administered transdermally in a gel-like matrix
were evaluated in nine patients with severe congestive
heart failure and in nine normal subjects. In normal
subjects, peripheral vasodilation was accompanied by
reflexsympathetic stimulation as reflected by an increase
in heart rate and plasma norepinephrine. In patients
with heart failure, nitroglycerin produced sustained
hemodynamic effects that began 30 minutes after the
application and fully persisted for at least 6 hours. A
significant decrease in right and left ventricular filling
pressures was associated with an increase in stroke index
and a significant decrease in forearm and pulmonary
vascular resistances. There was no change in heart rate
and systemic arterial pressure or in plasma norepineph-
The hemodynamic effects of nitroglycerin have been well
established as beneficial in the treatment of congestive heart
failure (l,2), but chronic administration has been less than
satisfactory because of short duration of action of the sub-
lingual form (3,4), inadequate absorption of the oral forms
and variability in efficacy of the topical ointment (4-6).
Other forms of nitrates have become popular for oral admin-
istration, but large doses may be required to produce a
satisfactory clinical response.
Several new preparations of nitroglycerin for cutaneous
administration have recently been introduced and now are
being widely used. Two of these preparations consist of
nitroglycerin in a gel-like matrix that is purported to provide
continuous transdermal absorption. Blood levels have been
reported to reach a steady level in 4 hours and persist for
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rine or plasma renin activity. After 24 hours, pressures
had partially returned to control levels, but mean pul-
monary artery pressure was still significantlylower than
in the control period.
After removal of the nitroglycerin, each patient ex-
hibited a decrease in cardiac index and an increase,
above the control values, in pulmonary and systemic
arterial pressures and pulmonary, systemic and forearm
vascular resistances. This transient rebound appeared
to be unrelated to stimulationof the sympatheticor renin-
angiotensin systems. Thus, transdermal absorption of
this new form of nitroglycerin appears to provide a ni-
trate vascular effect that is sustained for 24 hours, but
an endogenous vasoconstrictor effect may influence the
hemodynamic response over the first 24 hours.
24 hours after application of the nitroglycerin patch (7).
However, considerable controversy exists regarding the ac-
curacy of nitroglycerin blood level measurements, and their
relation to vascular effects is not entirely certain.
The purpose of this study was to evaluate the effects of
one of these new transdermal preparations in normal subjects
and patients with congestive heart failure. Hemodynamic
and neurohumoral evaluation allowed assessment of the
magnitude and duration of the circulatory response.
Methods
Patients. Nine patients (seven men and two women,
mean age 50.8 ± 11.9 years) with chronic congestive heart
failure were evaluated. Four subjects were in New York
Heart Association class III and five were considered to be
in class IV, with severe congestive heart failure relatively
refractory to conventional optimal therapy with digitalis and
diuretic drugs and large doses of oral vasodilator drugs.
Each patient was in stable condition when the hemodynamic
evaluation was performed. The diagnosis of heart failure
and the selection of the patients were made according to
our previously published criteria (8). Vasodilators were dis-
continued 72 hours before the hemodynamic study. Patients
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were maintained on daily digoxin; diuretic drugs were omit-
ted only on the day of the study. A previous study from
this laboratory (8) showed that plasma norepinephrine and
plasma renin activity were similar in patients with conges-
tive heart failure whether diuretic drugs were continued up
until the day of the study or were discontinued several days
prior to the study. Furthermore, hormone levels were stable
during a 3 day period of observation.
Studies were also carried out in nine normal volunteers
(six men and three women, mean age 28 ± 7. I years).
This study was approved by the Committee on the Use
of Human Subjects in Research of the University of Min-
nesota (January 1981). Written, informed consent was ob-
tained from each subject.
Procedures. Right heart catheterization was performed
and the brachial artery was cannulated. Complete details of
the invasive procedure and hemodynamic measurements have
been described previously (8). Cardiac output was measured
in triplicate by the thermodilution technique and systemic
vascular resistance (SVR) and pulmonary vascular resis-
tance (PVR) were calculated from the following formulas
in dynes-s-cm- 5:
SVR 80 X (MAP - RAP)/CO;
PVR 80 X MPP/CO,
where MAP = mean arterial pressure, RAP = mean right
atrial pressure, MPP = mean pulmonary artery pressure
and CO = cardiac output in liters/min.
Central venous blood samples were obtained for the mea-
surement of plasma renin activity by the radioimmunoassay
method of Sealey et al. (9) and plasma norepinephrine levels
by the radioenzymatic assay of Passon and Peuler (10), using
a CAT-A-KIT (Upjohn Company). Using this method, du-
plicate measurements taken in our laboratory have a coef-
ficient of variation of 8.4% for norepinephrine. Forearm
blood flow was measured by venous occlusion plethysmog-
raphy employing a Whitney mercury-in-rubber strain gauge
(II). Forearm vascular resistance was calculated by dividing
mean arterial pressure by the forearm blood flow and was
expressed in units of mm Hg/mlliOO g per min. Venous
capacitance was assessed by measuring the change in fore-
arm volume when an upper arm cuff was inflated to 30 mm
Hg and was expressed in ml/lOO g of tissue. In normal
subjects, systemic arterial pressure was measured directly
through an arterial cannula inserted into the brachial artery;
heart rate was monitored from an electrocardiographic lead.
Stroke volume was obtained with the Minnesota impedance
cardiograph, model 30413, using the formula of Kubicek
et al. (12). Previous studies (13) have shown that the imped-
ance method provides reliable estimation of stroke volume
in the absence of intracardiac shunts and valvular insuffi-
ciency. Blood samples for the measurement of plasma nor-
epinephrine and plasma renin activity were obtained through
a peripheral venous cannula.
Protocol. Patients were studied in the morning after an
overnight fast. After positioning of the catheters, baseline
measurements were obtained after at least 60 minutes of
supine rest. A 30 or 40 em? patch of a transdermal nitro-
glycerin preparation (Nitro-Dur) was then applied to the
chest of each patient with congestive heart failure. In normal
subjects, lower doses (10 to 20 cnr') of transdermal nitro-
glycerin were used.
The Nitro-Dur transdermal infusion system contains ni-
troglycerin in a gel-like matrix that is claimed by the man-
ufacturer to provide a steady release of nitroglycerin into
the skin. Hemodynamic and humoral measurements were
repeated after application of transdermal nitroglycerin in
each subject at 30 minutes and I, 2, 4 and 6 hours. After
6 hours, in patients with congestive heart failure, the hemo-
dynamic monitoring was continued in the coronary care unit
until the next morning. During this period only heart rate,
systemic arterial and diastolic pulmonary artery pressures
were recorded; cardiac output was not determined. After
the 24 hour complete hemodynamic and humoral measure-
ments, the nitroglycerin patch was removed. Measurements
were repeated at 30, 60, 90 and 120 minutes after the re-
moval of nitroglycerin in the patients with congestive heart
failure; normal subjects were monitored for I hour only
after removal of the patch.
Statistical analysis. Data are presented as mean ± stan-
dard deviation. Analysis of variance for repeat measure-
ments was used for statistical analysis of the data followed
by multiple comparison test, according to methods of Dun-
nett (14) and Tukey (IS).
Results
Responses in normal subjects (Table 1). Application
of nitroglycerin in normal subjects resulted in an increase
in forearm blood flow and a reduction in forearm vascular
resistance that became apparent after 2 hours and an increase
in heart rate that reached statistical significance at 4 hours.
Venous capacitance increased significantly from a mean
control value of 1.53 ± 0.16 to 1.96 ± 0.14 ml/lOO g in
the eight normal subjects in whom a satisfactory measure-
ment of venous capacitance could be obtained. The maximal
changes of venous capacitance occurred 2 to 4 hours after
application of nitroglycerin. Plasma norepinephrine levels
increased significantly by 2 hours but plasma renin activity
was unchanged. Arterial pressure, cardiac index and sys-
temic vascular resistance were not altered during the 6 hours
of monitoring. Removal of nitroglycerin was followed by
return of heart rate and plasma norepinephrine to the baseline
measurements in I hour while at the same time forearm
blood flow was significantly higher and resistance signifi-
cantly lower than in the control state.
Hemodynamic responses in congestive heart failure
(Table 2). In the nine patients with congestive heart failure,
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Table I. Hemodynamic and Hormon al Resp on se to Transderma l Nitroglycerin in N ine Normal Subjects
HR MAP CI SVR FVR FBF PNE
(beats/min) (mm Hg) (liters/min per rrr ' ) (dynes-s-cm - s) (units) (ml/ loo g per min ) (pg/ml)
Control 62.8 ± 7.0 82.0 ± 3.7 3.27 ± 0.49 1105 ± 199 49 3 ± 15.3 1.8 ± 0.6 122 ± IS
NTG 68.0 ± 7.0* 78.9 ± 3.5 3.42 ± 0.64 1035 ± 264 29.8 ± 13.2* 3 I ± 1.3* 163 ± 49t
(4 h)
Post-NTG 61.7 ± 6.6 79 .9 ± 8.5 32 1 ± 0.55 1115 ± 272 27.5 ± 83* 3.3 ± 0 .9* 141 ± 68
(I h)
*Dlfferences from contro l significant at p < 0.01; t Differences from control significant at p < 0.05 .
Differences between control values and values obtained 4 hours after the administration of transderma l nitrog lycerin (NTG) and I hour after its
removal (Post-NTG ) (mean values ± standard deviat ion). CI = card iac index; FBF = forearm blood flow; FVR = forearm vascular resistance ; HR
= heart rate: MAP = mean arterial pressure ; PNE = plasma norepinephr ine; SVR = systemic vascular resistance .
response to nitroglycerin began 30 minutes after the appli-
cation. A significant decrease in mean right atrial pressure,
mean pulmonary artery pressure, mean pulmonary wedge
pressure and pulmonary vascular resistance persisted for at
least 6 hours. Heart rate and mean systemic arterial pressure
were unchanged, and stroke index was significantly higher
than in the control state only at 6 hours. Although the total
systemic vascular resistancedid not change, the vasodi lating
effect of the drug was demonstrated by the significant de-
crease of the forearm vascular resistance in the seven pa-
tients in whom satisfactory measurements of forearm flow
could be obtained. Venous capacitance was significantly
higher than in the control state 4 hours after the application
of nitroglycerin .
Between 6 and 18 hours after the application, only a few
hemodynamic variables (heart rate, systemic arterial pres-
sure and diastolic pulmonary pressure) were monitored. Heart
rate and systemic arterial pressure were unchanged; in the
seven patients in whom satisfactory tracings were obtained,
diastolic pulmonary pressure remained constantly and sig-
Table 2. Time Course of Hemodynamic Re sponse to Transdermal N itroglycerin in Pat ients With Congestive He art Failure
Minutes After NTG
C 30 60 120 240 360 24 h
HR (beats/min) 86 .7 84.8 86.0 84. 3 84. 1 83.4 86.8
± 16.9 := 14.4 ± 14.7 :!: 16.9 ± 15.6 :!: 13.8 ± 10.4
RAP (mm Hg) 8.0 3.7 5.3 5 I 23 1.6 7.5
± 8.8 ± 4 5* ± 7.9* ± 6.9 t ± 4.8* ± 5.4 * :!: 7.6
PWP (mm Hg) 23.0 16.9 17.3 18 8 17.4 17.9 20 .0
± 8.5 :!: 7.9 * ± 8.3* ± 78t ± 9.0* ± 10.7* :!: 9.3
MPP (mm Hg) 35.2 29. 1 28.4 28.4 28.8 27.1 30.6
± 92 :!: 8.4* ± 9.9* ± 11.6* ± 10.7* ± 11.4* :!: 8.3 *
MAP (mm Hg) 80.6 77.3 77 8 79.3 76 .6 762 79.1
± 15.7 ± 14.3 :!: 15 2 :!: 17.0 :!: 15.6 :!: 15. 1 ± 15.6
SI (ml/bea t per rrr' ) 26.6 27.5 26.2 26.9 286 28.0 30. 1
± 9.9 ± 9.2 ± 9.4 ± 8.2 ± 10 1 ± 9.6 t ± 10.5
PVR (dynes-s-cm- 5) 705 557 594 554 537 525 605
± 296 ± 243 ± 332 ± 288 ± 279t ± 316t ± 347
SVR (dynes-s-cm t ') 1507 1481 1568 1481 1424 1417 1333
± 273 ± 313 ±364 ± 259 ± 332 ± 265 ± 402
FVR (units) 57 .0 51.4 55.6 42.3 39.6 39 .3 45 .9
± 18.7 ± 20. 1 ± 22.6 ± 14.6 ± 16.8t ± 16 2t ± 23. 1
FBF (ml/ IOO g per min) 1.7 1.8 1.7 2.0 2.2 2.2 2. 1
± 0 .6 ± 0 .9 ± 07 ± 0.5 ± 0 7 ± 0.7 ± 0 .8
VC (ml/IOO g) 1.35 1.60 1.52 1.53 1.86 1.68 1.56
± 0.27 ± 0.45 ± 0.57 ± 0 .70 ± 0.66t ± 0.96 ± 0.49
*Differences from control significant at p < 0.01 ; t Differences from control significant at p < 0.05 .
Values shown are mean ± standard deviation.
C = control state; MPP = mean pulmonary pressure; NTG = time intervals during transdermal nitroglycerin application; PVR = pulmonary vascular
resistance; PWP = pulmonary wedge pressure; RAP = right atnal pressure ; SI = stroke index; SVR = systemic vascular resistance; VC = venous
capacita nce: other abbrevitions as in Table I .
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nificantly lower than in the control state (22.8 ± 9.1 mm
Hg at 8 hours, 20.2 ± 7.8 at 12 hours, 21.6 ± 7.6 at 14
hours, 22.0 ± 6.2 at 18 hours versus 28.8 ± 5.9 mm Hg
in the control state, p < 0.01).
By 24 hours the hemodynamic effects of nitroglycerin
had partially waned. Pressures and resistances tended to be
lower than in the control period, but only mean pulmonary
artery pressure was significantly reduced. However, re-
moval of nitroglycerin was followed by transient but sig-
nificant hemodynamic changes suggesting that at 24 hours
the drug was still exerting a vascular effect. The magnitude
of these changes was variable, but a rebound effect was
seen in each patient from 30 to 90 minutes after removal
of the patch (Fig. I and 2). Mean arterial pressure, systemic
vascular resistance and pulmonary vascular resistance in-
creased to levels significantly higher than both the control
values and the 24 hour values, whereas the increase in
forearm vascular resistance and decrease in stroke index
were significant when compared with the 24 hour measure-
ments only. Although the rebound increase in mean pul-
monary wedge pressure from 20.0 ± 9.3 to 28.3 ± 7.2
mm Hg did not reach statistical significance, mean pul-
monary artery pressure increased after the removal of ni-
troglycerin from 30.6 ± 8.3 mm Hg to 37.8 ± 8.3 (prob-
ability [pJ < 0.05). No correlation between the magnitude
of the rebound and the observed hemodynamic response to
the nitroglycerin could be demonstrated. After 2 hours these
hemodynamic changes disappeared and no measurements
were significantly different from baseline control values.
Hormonal responses in congestive heart failure (Table
3). Plasma norepinephrine and plasma renin activity did
not change consistently during the 24 hour period that the
patch was applied or after its removal. The insignificant
increase noted after nitroglycerin administration was due to
an unexplained large increase in plasma norepinephrine in
three patients and plasma renin activity in one patient. These
patients did not exhibit an unusually prominent hemody-
namic rebound.
Side effects. No side effects from the drug were ob-
served in the patients with heart failure. In contrast, all of
the normal subjects complained of headache and three ex-
perienced nausea and vomiting despite use of a lower dose
and evidence of a very modest hemodynamic effect. These
symptoms subsided in less than 30 minutes after removal
of the drug patch.
Discussion
Hemodynamic and hormonal effects. The hemody-
namic response to transdermal nitroglycerin in normal sub-
jects was, in our study, not different from the response to
sublingual nitroglycerin or nitroglycerin ointment described
previously (16,17). Although systemic arterial pressure was
unchanged, peripheral vasodilation occurred as suggested
by an increase in forearm blood flow and venous capaci-
tance, and reflex sympathetic stimulation was reflected by
a significant increase in plasma norepinephrine and heart
rate. In patients with congestive heart failure, transdermal
nitroglycerin was effective in reducing cardiac filling pres-
sures and pulmonary artery pressure and increasing stroke
index. The lack of reflex increase in heart rate and plasma
norepinephrine in response to peripheral vasodilation is
not unusual in patients with chronic heart failure (18,19).
Previous studies (20) demonstrated that a subset of patients
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with congestive heart failure have striking abnormalities of
both low pressure mechanoreceptors and baroreceptors such
that these patients fail to respond with an increase in heart
rate and plasma norepinephrine to a decrease in either atrial
or arterial pressure. It is still not understood why low doses
of nitroglycerin produce unpleasant side effects in normal
subjects but high doses are tolerated by patients with heart
failure.
The vasodilating effect of nitroglycerin on the cutaneous
or muscular arterial beds, or both, demonstrated by the
significant decrease in forearm vascular resistance, must be
associated with vasoconstriction in other regional beds be-
cause there was no decrease in the total systemic resistance.
The different regional vasodilating effect of nitroglycerin,
previously pointed out by other investigators (21,22), may
be dependent on the predrug level of vasomotor tone (23),
and on regional differences in endothelial synthesis of pros-
tacyclin (24).
Duration of effects. The 24 hour hemodynamic data
could suggest that the nitroglycerin effect had waned, be-
cause at that time only mean pulmonary artery pressure was
significantly lower than in the control period. Needleman
and Johnson (25) demonstrated that tolerance to nitroglyc-
erin occurs at the level of vascular smooth muscle and sug-
gested that a reaction with reduced sulfhydryl groups con-
verts the nitrate receptor to a form that has a lower affinity
for nitroglycerin. This reaction is time-dependent and it
could explain, in part, why a partial attenuation of the hemo-
dynamic effect of transdermal nitroglycerin was observed
only after a number of hours of administration. Because
nitroglycerin blood levels were not measured in our study,
a decrease in nitroglycerin absorption or an increase, or
both, in nitrate metabolism could not be excluded. However,
even if at 24 hours nitroglycerin blood levels were lower,
the transient striking hemodynamic changes that followed
removal of nitroglycerin suggest that the vascular effect was
still present at 24 hours but may have been actively
counteracted.
Pathophysiology of waning of hemodynamic effect and
of rebound. It has been postulated that withdrawal from
nitroglycerin results in unopposed coronary and systemic
vasoconstriction, and coronary spasm has been angiograph-
ically documented in dynamite workers with normal
coronary arteries (26). The possibility of development of
Table 3. Response of Plasma Norepinephrine (PNE) and Plasma Renin Activity (PRA) to Transdermal Nitroglycerin in Patients With
Congestive Heart Failure
Time (min) After NTG
C 30 60
PNE 844 ± 714 660 ± 830 784 ± 909
(pg/ml)
PRA 7.4 ± 7.7 5.2 ± 4.4 6.4 ± 74
(ng/ml per h)
120
636 ± 570
5.6 ± 6.7
240
875 ± 985
66 ± 7.4
360
776 ± 1158
5.9 ± 7.8
24 h
870 ± 1071
6.7 ± 6.5
Post-NTG
1186 ± 1797
8.2 ± 8.6
Values shown are mean values ± standard deviation.
Abbreviations as in Tables I and 2.
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with isosorbide dinitrate was advanced by Franciosa et al.
(27), who noted hemodynamic deterioration and two sudden
deaths soon after the discontinuation of nitrates. The path-
ophysiology of the waning of hemodynamic effect at 24
hours and the rebound when the patch was removed is not
clear. A possible explanation is reflex activation of the sym-
pathetic or renin-angiotensin systems, stimulated by the re-
duction in intracardiac and arterial pressures. With the re-
moval of nitroglycerin, the direct vasodilating effect of the
drug would disappear, thus leaving the vasoconstrictor
mechanisms unopposed. Activation of the renin-angiotensin
system has been suggested (28) to be responsible for hy-
pertension during anesthesia after withdrawal of sodium
nitroprusside. because it was attenuated by captopnl.
Enhanced activity of the sympathetic and renin-anglo -
tensin systems has been proposed as a mechanism for the
hemodynamic rebound and the development of tolerance to
vasodilator drugs in patients with congestive heart failure
(29,30) but was not supported by hormonal determinations.
In conscious dogs, Vatner (22) showed a biphasic response
to systemic nitroglycerin consisting of initial arteriolar vas-
odilation followed. during the later phase of the infusion,
by vasoconstriction in the mesenteric and iliac beds. The
early vasodilation was most likely due to the direct effect
of the drug on the vascular smooth muscle. whereas the
latter effects were attributed to a reflex vasoconstriction
because they were not observed during intraarterial admin-
istration or after deafferentation. In our patients with heart
failure. however. neither plasma norepinephrine nor plasma
renin activity increased significantly during or after nitro-
glycerin administration. Therefore. it is unlikely that the
attenuation of the hemodynamic effect and the rebound de-
terioration of cardiac function are exclusively due to acti-
vation of these vasoconstrictor forces. These data are in
agreement with those of Francis et al. (31l. who showed a
rebound increase. above the control values, in systemic
vascular resistance after nitroprusside withdrawal without a
concomitant increase in circulating plasma norepinephrine,
plasma renin activity or plasma vasopressin.
Therapeutic implications. These studies provide some
insight into the efficacy of a new transdermal form of ni-
troglycerin. but they do not establish its clinical usefulness.
The magnitude of hemodynamic effect of the transdermal
preparation was less than the peak effect observed with
sublingual or oral forms of nitrates. but this might be ex-
pected from a drug achieving a steady blood level rather
than peaks and valleys after bolus administration. The du-
ration of action (probably at least 24 hours) appears to be
longer than that observed with other forms of nitrates. but
the warung of effect after 6 hours and hemodynamic rebound
raise the possibility that the limited duration of effect re-
ported after oral and cutaneous nitroglycerin administration
(4) could be influenced by an endogenous vasoconstnctor
mechanism. Additional studies are needed to determine
whether this vasoconstrictor mechanism persists during long-
term administration of nitroglycerin and whether it may play
a role in the long-term response to vasodilator therapy or
its discontinuation.
Ada Simon. PhD. Timothy Cox and Kathleen Trudeau provided valuable
technical assistance. The secretarial aid of Susan Johanson and Wendy
Markuson was greatly appreciated. Transdermal nitroglycerin (Nitro-Our)
was kindly supplied by Allyn Golub, MD. from Key Pharmaceuticals.
Inc.. Miami. Florida.
References
I . Gold HK, Leinbach RC. Sanders CA. The use of sublingual nitro-
glycerin In congestive failure following acute myocardial infarction.
Circulation 1972;46 :839-45
2 Franciosa JA. Mikulic E. Cohn IN. Jose E. Fabie A. Hemodynamic
effec ts of orally administered isosorbide dinitrate in patients with
congestive heart failure. Circulation 1974;50. 1020-4.
3. Gray R. Chatterjee K. Vyden JK. Ganz W. Forrester JS. Swan HJC
Hemodynamic and metabolic effects of rsoso rbrde dm itrate in chronic
congestive heart failure Am Heart J 1975:90 '346- 52.
4 Franciosa JA. Blank RC. Cohn I N. Mikulic E. Hemodynamic effects
of topical. oral and sublingual nitroglycerin In left ventricular failure
Curr Therap Res 1977.22:231- 45.
5 Taylor WR. Forrester JS. Magnusson P. Takano T. Chatterjee K.
Swan HJC Hemodynarruc effect of rutroglycen n Ointment In conges-
uvc heart failure. Am J Cardiol 1976.38.469- 73.
6 Armstrong PW. Armstrong JA. Marks GS. Pharrnacokineuc-hemo-
dynarmcstudies of nitroglycerin ointment In congestive heart failure.
Am J Cardrol 1980:46.670- 6.
7 Colfer H. Stetson P. Lucchesi BR. Wagner 1. Pitt B. The nitroglycerin
polymer gel matrix system: a new method for administering nitrogly-
ccnn evaluated With plasma mtroglyccnn level J Cardiovasc Phar-
macol 1982.4:52 1-5
8 Levine TH. FrancrsGS. Goldsmith SR. Simon AB. Cohn IN Activity
of the sympathetic nervous system and renin-angiotensin system as-
sessed by plasma hormone levels and their relationship to hernody-
narruc abnorrnahties In congestive heart failure. Am J Cardiol
I'IK2.49.165'1-66
9. Sealey JE. Gerten-Banes 1. Laragh JH. The renin system. variations
In man measured by radronnmunoassay or bioassay. Kidney Int
1972: 1.240- 53
10 Passon PG. Peuler JD. A Simplified radiometric assay for norepi-
nephrine and epmephn ne Anal Biochem 1973:5 1:6 18-31
II . Mason DT. Braunwald E. A simpltfied plethysmographic system for
the measurement of -ystermc artenal pressure and peripheral blood
flow Am Heart J 1962:64:796- 801
12. Kubicek WG. Karnegi-, IN . Patterson RP. Witsoe DA. Malison RH.
Development and evaluation of an Impedance cardiac output system.
Aerospace Med 1966:37.1208-1 2
13 Snnth J1. Bush JE. Wicdrnerer VT. Tnstaru FE Application of Imped-
ance cardiography to the study of postural stress. J Appl Physiol
1970.29 133-7.
14 . Dunnett CW New tables for multiple compansons With a control.
Biometries 1964;20'482-91
15 Tukey JW. Comparing mdividual means In the analysis of variance.
Btorne tnc s 1949 ,599-114
16 Mason DT. Braunwald E The effects 01rutroglycenn and amyl nitnte
on arteriolar and venous tone In the human forearm. Circulation
1965,32.755-66.
878 OLIVARI ET AL.
TRANSDERMAL NITROGLYCERIN IN HEART FAILURE
rxcc Vol. 2. No 5
November 1983 872- 8
17. Ogasawara B, Ogawa K, Sassa H. Effects of nitroglycerin ointment
on plasma norepinephrine and cyclic nucleotides in congestive heart
failure . J Cardiovasc Pharmacol 1981;3:867-75 .
18. Goldstein RE. Beiser GO, Stampfer M, Epstein SE . Impairment of
autonomically mediated heart rate control In patients with cardiac
dysfunct ion. Circ Res 1975.26:571 -8.
19. Eckberg DL, Drabinsky M. Braunwald E. Defective cardiac parasym-
pathenc control in patients with heart disease. N Engl J Med
1971;285:877- 83.
20. Olivari MT, Levine TB. Cohn IN. Abnormal neurohumoral response
to nitroprusside infusion in congestive heart failure. J Am Coli Cardiel
1983;2:411- 7.
21. Ferrer MI. Bradley SDE , Wheeler HO, et al Some effec ts of nitro-
glycerin upon the splanchnic. pulmonary and systemic circulations .
Circulation 1966;33:357-73.
22. Varner SF. Pagani M, Rutherford 10. Millard RW, Manders WT .
Effect of nitroglycerin on cardiac function and regional blood flow
distribution in conscious dogs. Am J Physiol I978;234:H244-52.
23. Kadowitz PJ, Nandiwada P, Gruetter CA , Ignarro U . Hyman AL.
Pulmonary vasodilator responses to nitroprusside and nitroglycerin in
the dog. J Clin Invest 1981;67:893- 902.
24. Levin RI. Jaffe EA. Weksler BB, Tack-Goldman K. Nitroglyce rin
strmulates synthesis of prostacyclin by cultured human endot helial
cells. J Clin Invest 1981;67:762- 9.
25. Needleman P. Johnson EM. Mechan ism of tolerance development to
orgamc nitrates. J Pharmacol Exp Ther 1973;184:709-15 .
26. Klock Jc. Non-occlusive coronary disease after chronic exposure to
nitrates: evidence for physiologic nitrate dependence . Am Heart J
1975;89:510-3 .
27. Franciosa JA , Nordstro m LA, Cohn IN . Nitrate therapy for congestive
heart failure. JAMA 1978;240:443-6 .
28. Khambatta HJ, Stone JG. Kham E. Hypertension during anesthesia
on discontinuation of sodium nitroprusside-induced hypotension .
Anesthesiology 1979;51:127-30.
29. Packer M, Meller 1. Medina N, Yushak M, Gorlin R. Determinants
of drug responses In severe chronic heart fatlure . I . Activation of
vasoconstrictor forces during vasodifatory therapy. Circulation
1981;64:506- 14.
30. Colucci WS, Wilham s GH, Alexander RW, Braunwald E. Mecha-
nisms and implication s of vasodilator tolerance in the treatment of
congestive heart failure. Am J Med 1981;71:89-99.
31. Francis GS. Olivan MT. Goldsmith SR, levine TB . Pierpont G. Cohn
IN . The acute response of plasma norepinephrine, renin activity and
argin ine vasopressin to short-term rntroprusside and nitroprusside
withdrawal in patients with congestive heart fatlure . Am Heart J ( In
press).
